secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064423
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reports Q1 net loss $28.2M ($0.31/sh); cash $150.4M; expects data readouts in 2H 2025
--------------------------------------------------------------------------------

- Net loss $28.2M ($0.31 per share) vs $28.0M loss in Q1 2024; R&D spending $22.8M.
- Cash $150.4M as of Mar 31, 2025; company expects to fund operations into 2H 2026.
- Phase 1 trial of ADI-001 in autoimmune diseases expanded to LN/SLE; preliminary data expected 2H 2025.
- Phase 1 trial of ADI-270 in metastatic/advanced ccRCC ongoing; preliminary data expected 2H 2025.
- Michael Grissinger appointed to board; FDA granted Fast Track for ADI-001 in SLE and SSc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025064423/0000950170-25-064423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000095017025064423/acet-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer